RNA polymerase B subunit gene mutations in biofilm-embedded methicillin-resistant Staphylococcus aureus following rifampin treatment

Abstract

We documented high rifampin resistance induction activity when MRSA was engaged in biofilm with rifampin exposure. Monotherapy seems to be inadequate for MRSA in biofilm. There is an urgent need for developing effective combination therapies with less rifampin resistance-inducing activities for treating MRSA in biofilms.

Comparative genomics of phenotypic antimicrobial resistances in methicillin-resistant Staphylococcus pseudintermedius of canine origin

“…In this study resistance to rifampicin was seen in only one isolate and coincided with a mutation in rpoB. As the position of this mutation His to Pro at amino acid position 481, differs from the one previously described in S. pseudintermedius (Kadlec et al, 2011), it is difficult to ascertain that this mutation is associated with resistance, however resistance conferring mutations 481 His→Tyr and 481 Hi-s→Asn have been described in S. aureus (Wichelhaus et al, 2002;Tang et al, 2016), making this highly likely.…”

Development of a Dual-Acting Antibacterial Agent (TNP-2092) for the Treatment of Persistent Bacterial Infections

“…Rifampin has demonstrated good activity against pathogens living in bacterial biofilms in vitro and in animal models of biofilm-associated, persistent infections , and is recommended as a key component in the treatment of PJIs according to various clinical practice guidelines. , The contribution of rifampin in the management of PJIs has been demonstrated in many clinical trials. , It has been well documented that rifampin should always be used in combinations with other antibiotics to minimize the development of resistance . In addition, the companion antibiotic can help to kill planktonic bacterial and prevent bacteremia.…”

Better Completion of Pediatric Latent Tuberculosis Treatment Using 4 Months of Rifampin in a US-based Tuberculosis Clinic

“…Monotherapy with rifampin has been associated with rapid development of resistance in typical bacterial infections, most notably Staphylococcus aureus. 17 Selection for rifampin resistance during monotherapy has been clearly demonstrated in active TB. 18 The lower bacillary burden in pediatric LTBI should serve to significantly lower the risk of development of rifampin resistance, but this has not been explicitly demonstrated in the case of 4R regimens.…”